Latest Industry Insights

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

This article discusses the methodology of using common archived biospecimens for RNA sequencing in oncology applications, such as tumor profiling, introducing challenges and innovative solutions.

Hans van der Voorn tells us about some of the recent progress in the extracellular vesicle-based diagnostics and therapeutics landscape, particularly the need for industrial-scale EV isolation workflows.

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

At AACR 2023, Technology Networks spoke with Dr. Mark Garner, global cancer segment market manager at Agilent Technologies, to learn how the new SureSelect Cancer CGP assay is empowering the cancer research field.

The 10-year anniversary of SWATH DIA signifies a period of immense growth that is only expected to continue to evolve, influencing a wide range of fields. This article explores key milestones for SWATH DIA since its development.

In this interview, Technology Networks spoke to Dr. Cameron Pitt to learn more about KRAS as a target for cancer therapeutics, avoiding known resistance mechanisms and the effectiveness of two novel KRAS inhibitors.

In this opinion piece, Dr. Gen Li discusses how AI and predictive analytics are transforming oncology clinical trials.

To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.